Keros Therapeutics reports Q4 2022 net loss of $29.7M; cash runway into Q3 2025

Keros Therapeutics, Inc.

Net loss of $29.7M for Q4 2022 vs $6.9M in Q4 2021; full year net loss $104.7M vs $58.7M.
No revenue in 2022; 2021 revenue of $20.1M from Hansoh license agreement.
R&D expenses $24.9M in Q4 2022, up from $18.8M; driven by Phase 2 trials of KER-050.
Cash and equivalents $279.0M at Dec 31, 2022; with ATM proceeds, funds operations into Q3 2025.
Anticipated 2023 milestones: complete MDS trial enrollment, report additional data for KER-050, KER-047, KER-012.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Keros Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2022 results: net income net loss of $29.7 million for the fourth quarter and $104.7 million for the year ended December 31, 2022.

Period: the fourth quarter and full year ended December 31, 2022
Net income: net loss of $29.7 million for the fourth quarter and $104.7 million for the year ended December 31, 2022
Result: reported results

Exact text from the filing

Keros Therapeutics, Inc. (the “Company”) issued a press release announcing its recent business highlights and financial results for the quarter and year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Keros Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001664710-23-000020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.